Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04001374 · ClinicalTrials.gov registry record

Platelet Sub-study of the TWILIGHT Trial

A clinical trial of Coronary Artery Disease and Myocardial Infarction, sponsored by Juan Badimon.

Completed
Registry status
40
Enrollment target
1
Study location

NCT04001374: Completed study of Coronary Artery Disease and Myocardial Infarction, sponsored by Juan Badimon.

NCT04001374 is a study of Coronary Artery Disease and Myocardial Infarction that has completed, run by Juan Badimon. The registered enrollment target is 40 participants, below the 1,287-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04001374, a study of Coronary Artery Disease and Myocardial Infarction, has completed, sponsored by Juan Badimon.

COMPLETED
Registry status
40 participants
Enrollment target
1
Study location

Study Summary

TWILIGHT study is a multicenter RCT comparing treatment with ticagrelor alone versus ticagrelor plus aspirin in high-risk patients after PCI. All patients will receive DAPT (ticagrelor plus aspirin) for the initial 3 months post-PCI and then be randomized to either Ticagrelor alone OR Ticagrelor plus Aspirin DAPT. To investigate the pharmacodynamic effects of the two treatments in this trial, a 'Platelet Sub-study' will be conducted only at the Mount Sinai Medical Center. The sub-study will recruit randomized patients from the TWILIGHT Trial at Mount Sinai and conduct specialized blood tests at randomization and one month thereafter. The aim of the Platelet Sub-study is to compare the antithrombotic effects of Ticagrelor alone versus Ticagrelor plus Aspirin using an ex vivo model of thrombosis (Badimon Chamber).

Primary Outcome

Thrombus area measured 1-6 months after randomization

Interventions

  • DRUG Ticagrelor
  • DRUG ASA

Study Locations (1)

New York

  • Icahn School of Medicine at Mount Sinai - New York

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2015-06-28
Est. Completion 2018-02-28
Juan Badimon

2 total trials

What the finished NCT04001374 record still lists

NCT04001374 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 1,287-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (97% lower).

The record links to 2 conditions, with Coronary Artery Disease appearing as the primary indexed condition, and to 2 interventions - of which Ticagrelor is the first listed.

NCT04001374 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT04001374 about?

NCT04001374 is a clinical study titled "Platelet Sub-study of the TWILIGHT Trial". TWILIGHT study is a multicenter RCT comparing treatment with ticagrelor alone versus ticagrelor plus aspirin in high-risk patients after PCI. All patients will receive DAPT (ticagrelor plus aspirin) for the initial 3 months post-PCI and then be randomized to either Ticagrelor alone OR Ticagrelor plu...

What is the current status of trial NCT04001374?

This trial is currently completed. The enrollment target is 40 participants. The study started on 2015-06-28. Estimated completion is 2018-02-28.

What conditions does trial NCT04001374 study?

This clinical trial studies the following conditions: Coronary Artery Disease, Myocardial Infarction.

What interventions are being tested in trial NCT04001374?

The interventions under investigation include: Ticagrelor (DRUG), ASA (DRUG).

Who is sponsoring clinical trial NCT04001374?

This trial is sponsored by Juan Badimon, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04001374 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Coronary Artery Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04001374's enrollment target sits among peer trials

40 188th of 219 higher than 27 of 219 other Coronary Artery Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Coronary Artery Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04001374, the US trial registry maintained by the National Library of Medicine. NCT04001374 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.